Carcinoma, Neuroendocrine  >>  Lipotecan (TLC388)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lipotecan (TLC388) / Taiwan Liposome Company
NCT02457273: Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients

Completed
2
23
RoW
TLC 388, Lipotecan®,
National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Taichung Veterans General Hospital, National Cheng-Kung University Hospital, Chang Gung Memorial Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital
Neuroendocrine Carcinomas
04/18
12/18

Download Options